Veterinary Pharmacovigilance Market Size & Growth Forecast 2027–2036, By Segments (Solution, Type, Product, Animal Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Veterinary Pharmacovigilance Market size was valued at USD 1.13 billion in 2026 and is anticipated to grow at a 12.92% CAGR from 2027 to 2036, surpassing USD 3.81 billion by 2036. The industry revenue for 2027 is assessed at USD 1.25 billion.
Get more details on this report
Request Free Sample ReportVeterinary Pharmacovigilance Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 42.40% share in 2026 due to its established animal health ecosystem, structured adverse event reporting practices, and strong participation from pharmaceutical and veterinary service organizations.
- Asia Pacific is projected to expand at a 14.9% CAGR, driven by increasing veterinary medicine use, broader access to animal healthcare, and stronger focus on formal drug safety monitoring.
Segment Momentum
- Software held a 53.55% share in 2026 because it enables standardized adverse event reporting, case processing, regulatory documentation, and compliance through consistent, traceable workflows.
- Contract outsourcing is the fastest-growing type segment as organizations seek scalable pharmacovigilance expertise and operational flexibility without expanding internal teams.
Market Expansion Drivers
- Increasing veterinary drug approvals strengthening post-market safety monitoring requirements.
- Rising pet ownership and livestock health awareness increasing pharmacovigilance demand.
- AI-driven adverse event detection improving pharmacovigilance reporting efficiency.
Leading Market Participants
- Top players in the veterinary pharmacovigilance market include ArisGlobal LLC (United States), Accenture plc (Ireland), Ennov Group (France), Sarjen Systems Pvt. Ltd. (India), ProductLife Group (France), knoell Germany GmbH (Germany), Biologit Holding AB (Sweden), Indivirtus AB (Sweden), Oy Medfiles Ltd. (Finland), IQVIA Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.13 billion
- 2027 Estimated Market Size: USD 1.25 billion.
- Projected Market Size: USD 3.81 billion by 2036
- Growth Forecast: 12.92% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Software (Solution) | In-house (Type) | Anti-Infective (Product) | Dogs (Animal Type)
- Emerging Opportunity Segment: Services (Solution) | Contract Outsourcing (Type) | Biologics (Product) | Cats (Animal Type)
Market Growth Drivers and Industry Trends
Increasing veterinary drug approvals strengthening post-market safety monitoring requirements
Increasing veterinary drug approvals will propel the veterinary pharmacovigilance market as a broader range of products requires structured safety monitoring after entering use. Post-market surveillance helps identify and assess adverse events associated with veterinary medicines, strengthening the need for systems and processes that support ongoing safety oversight.
Rising pet ownership and livestock health awareness increasing pharmacovigilance demand
The veterinary pharmacovigilance market is gaining importance as rising pet ownership and greater awareness of livestock health increase attention to the safe use of veterinary medicines. Growing emphasis on animal health encourages closer monitoring of treatment outcomes and potential adverse events, creating additional demand for pharmacovigilance activities across veterinary applications.
AI-driven adverse event detection improving pharmacovigilance reporting efficiency
AI-driven adverse event detection will support the veterinary pharmacovigilance market by improving the efficiency of identifying and processing safety-related information. Automated analysis can help organizations handle pharmacovigilance reports more effectively, allowing relevant adverse event signals to be identified and evaluated within increasingly technology-enabled veterinary safety monitoring workflows.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Regulatory requirements for veterinary drug safety | 4.00% | Short term (≤ 2 yrs) | North America, Europe | High | Fast |
| Rising adoption of pharmacovigilance software | 4.50% | Medium term (2–5 yrs) | North America, Asia Pacific | Medium | Moderate |
| Expansion of veterinary healthcare services | 4.80% | Long term (5+ yrs) | Asia Pacific, Latin America | Low | Slow |
| Increasing veterinary drug approvals strengthening post-market safety monitoring requirements | 3.20% | High | North America, Europe | High | Near Term |
| Rising pet ownership and livestock health awareness increasing pharmacovigilance demand | 3.00% | Moderate | North America, Asia Pacific | High | Near Term |
| AI-driven adverse event detection improving pharmacovigilance reporting efficiency | 2.60% | High | Europe, North America | Emerging | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America dominated the veterinary pharmacovigilance market with a 42.40% share in 2026, reflecting a mature veterinary healthcare ecosystem and strong emphasis on the safety, efficacy, and post-market monitoring of animal medicines. The region benefits from established veterinary regulatory frameworks, widespread use of pharmaceutical treatments, and increasing awareness among veterinarians and animal owners regarding adverse drug reactions. Growing companion animal ownership, expanding preventive healthcare practices, and greater adoption of advanced veterinary therapies are generating a stronger need for systematic safety surveillance and reliable pharmacovigilance processes.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is positioned as the fastest-growing region as expanding veterinary healthcare access, rising companion animal ownership, and increasing livestock production create broader demand for safe and effective animal medicines. Improvements in veterinary infrastructure and greater awareness of animal health are encouraging more structured monitoring of pharmaceutical products. Regulatory modernization, growing adoption of preventive veterinary care, and increasing use of specialized medicines are also supporting the development of pharmacovigilance practices, particularly as healthcare stakeholders place greater emphasis on treatment safety and responsible medication management.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
Germany 🇩🇪
Regulatory Compliance SystemsGermany is reinforcing veterinary pharmacovigilance with comprehensive safety documentation and standardized reporting practices. Organizations are investing in data quality, signal detection, and compliance processes to support responsible animal health product management.
France 🇫🇷
Veterinary Data CoordinationFrance is strengthening veterinary pharmacovigilance through coordinated safety data collection across animal healthcare providers. Industry participants are prioritizing consistent reporting practices and proactive evaluation of medicine safety to support regulatory expectations.
Italy 🇮🇹
Clinical Safety DocumentationItaly is enhancing veterinary pharmacovigilance by improving documentation standards for adverse event reporting across companion and livestock healthcare. Companies are focusing on efficient case management and regulatory compliance to support safe therapeutic use.
Japan 🇯🇵
Companion Animal SurveillanceJapan is increasing attention to veterinary pharmacovigilance as companion animal healthcare expands and therapeutic options diversify. Companies are enhancing adverse event monitoring and evidence collection to improve product safety throughout the lifecycle.
South Korea 🇰🇷
Integrated Reporting NetworksSouth Korea is improving veterinary pharmacovigilance by connecting manufacturers, veterinary clinics, and regulatory stakeholders through more coordinated reporting systems. The market emphasizes timely safety evaluations and stronger pharmacovigilance workflows for animal medicines.
United States 🇺🇸
Digital Safety MonitoringThe U.S. continues expanding veterinary pharmacovigilance through structured adverse event reporting and digital surveillance platforms. Pharmaceutical companies are strengthening post-market safety monitoring while improving collaboration with veterinary professionals and regulatory authorities.
Veterinary Pharmacovigilance Market Share (%), by Solution, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportSolution Segment Analysis: Software (Largest Segment) vs Services (Fastest-Growing Segment)
Software held the largest share of the veterinary pharmacovigilance market in 2026, supported by the increasing need to organize, process, and monitor large volumes of animal safety data. Pharmacovigilance software facilitates adverse event reporting, case management, data integration, signal detection, and regulatory documentation, enabling veterinary pharmaceutical stakeholders to manage safety information more systematically. Growing emphasis on data accuracy, traceability, and timely safety assessment is strengthening the role of digital platforms in veterinary drug surveillance.
Services represent the fastest-growing segment as organizations increasingly seek specialized support for pharmacovigilance activities that require regulatory expertise and dedicated operational capabilities. Outsourced services can assist with adverse event processing, safety monitoring, reporting, and compliance management, allowing organizations to access specialized resources while focusing internal teams on core development and commercial activities. Increasing complexity in veterinary drug safety requirements is further encouraging demand for flexible and expert-led pharmacovigilance services.
Type Segment Analysis: In-house (Largest Segment) vs Contract Outsourcing (Fastest-Growing Segment)
In-house operations accounted for the largest share of the veterinary pharmacovigilance market in 2026, reflecting the preference of established organizations to retain direct control over safety monitoring and regulatory processes. Internal teams can maintain close oversight of product safety information, integrate pharmacovigilance activities with broader drug development and quality functions, and respond efficiently to organization-specific requirements. Direct access to internal product knowledge also supports consistent evaluation and management of veterinary safety data.
Contract outsourcing is the fastest-growing segment as veterinary pharmaceutical organizations increasingly seek specialized expertise and scalable operational support. External providers can manage resource-intensive pharmacovigilance activities while offering access to specialized personnel, established processes, and regulatory capabilities. The need to improve operational flexibility and manage increasingly complex safety-monitoring responsibilities is encouraging greater use of outsourced models.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Solution | Software, Services | Software | Services |
| Type | In-house, Contract Outsourcing | In-house | Contract Outsourcing |
| Product | Biologics, Anti-Infective, Others | Anti-Infective | Biologics |
| Animal Type | Dogs, Cats, Others | Dogs | Cats |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Major players in the veterinary pharmacovigilance market:
1. ArisGlobal LLC (United States)
2. Accenture plc (Ireland)
3. Ennov Group (France)
4. Sarjen Systems Pvt. Ltd. (India)
5. ProductLife Group (France)
6. knoell Germany GmbH (Germany)
7. Biologit Holding AB (Sweden)
8. Indivirtus AB (Sweden)
9. Oy Medfiles Ltd. (Finland)
10. IQVIA Inc. (United States)
Strengthening animal healthcare regulations are encouraging innovation in the veterinary pharmacovigilance market, with increasing adoption of digital safety monitoring platforms and advanced adverse event reporting systems. Improved pharmacovigilance practices are supporting better regulatory compliance and medication safety management.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| ArisGlobal LLC (United States) | |||||||
| Accenture plc (Ireland) | |||||||
| Ennov Group (France) | |||||||
| Sarjen Systems Pvt. Ltd. (India) | |||||||
| ProductLife Group (France) | |||||||
| knoell Germany GmbH (Germany) | |||||||
| Biologit Holding AB (Sweden) | |||||||
| Indivirtus AB (Sweden) | |||||||
| Oy Medfiles Ltd. (Finland) | |||||||
| IQVIA Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Merck Animal Health | Feb-25 | Merck Animal Health’s BRAVECTO injectable formulation received recognition as Best New Companion Animal Product, supporting year-long flea and tick protection in dogs. The product is integrated within veterinary pharmacovigilance frameworks to ensure ongoing safety and efficacy monitoring across multiple international markets. |
| Dechra Pharmaceuticals PLC | Jul-24 | Dechra Pharmaceuticals PLC acquired Invetx, expanding its companion animal therapeutics portfolio with monoclonal antibody-based treatments. The acquisition enhances its biologics pipeline and strengthens capabilities in developing advanced veterinary medicines with improved safety and targeted therapeutic outcomes. |
| Merck Animal Health | Jun-24 | Merck Animal Health obtained USDA approval for the NOBIVAC NXT Canine Flu H3N2 vaccine based on RNA-particle technology, expanding its canine influenza prevention portfolio while incorporating pharmacovigilance monitoring to ensure product safety and regulatory compliance. |
| European Medicines Agency (EMA) | Jan-22 | The European Medicines Agency implemented an enhanced veterinary pharmacovigilance system aligned with updated regulatory frameworks and VICH reporting standards, improving adverse event monitoring and regulatory oversight of veterinary medicinal products across the European Union. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Veterinary Pharmacovigilance Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Pharmacovigilance Activity | Adverse Event Collection, Case Processing & Assessment, Signal Detection & Management, Regulatory Reporting |
| Stakeholder Type | Veterinary Pharmaceutical Manufacturers, Animal Health Distributors, Veterinary Healthcare Providers, Regulatory Authorities |
| Reporting Channel | Spontaneous Reporting, Clinical & Post-Marketing Studies, Literature Monitoring, Digital & Electronic Reporting |
Veterinary Pharmacovigilance Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Pharmacovigilance Digitization Roadmap |
|
| Global Regulatory Harmonization Analysis |
|
| Veterinary Product Lifecycle Risk Assessment |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the current size of the veterinary pharmacovigilance market?
How is the veterinary pharmacovigilance industry size expected to evolve during the forecast period?
How is increasing regulatory and post-market surveillance pressure shaping pharmacovigilance operations in animal health?
Why is contract outsourcing gaining momentum in veterinary pharmacovigilance operations?
Why is software the largest solution segment in the veterinary pharmacovigilance market?
Which type segment is growing fastest in the veterinary pharmacovigilance market?
Why does North America dominate the veterinary pharmacovigilance market?
What is accelerating veterinary pharmacovigilance adoption in Asia Pacific?
Who are the leading players in the veterinary pharmacovigilance landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook